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nation plus either antidepressants (12.2%), mood-stabi-
lizers (10.5%), or both (9.9%); and antipsychotics alone
(9.6%). Greater severity, female, paranoid or schizoaf-
fective diagnoses, non-teaching and for-proﬁt hospitals
were associated with increased polypharmacy use.
Patients in public programs (Medicaid/Medicare) received
less atypical antipsychotics but more polypharmacy com-
pared to those in managed care and commercial pro-
grams. Atypical antipsychotic use increased and lithium
use decreased from 1999–2001. CONCLUSIONS:
Polypharmacy is common among hospitalized schizo-
phrenia patients. Patient and institution characteristics
inﬂuenced treatment.
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OBJECTIVES: The Clinical Care GroupsTM (CCG) soft-
ware transforms fragmented claims data into episodes of
medical conditions. The results of health care claims data
grouped by CCG indicate that many SSRI claims are not
grouped into a medically related episode. Our objective
is to describe the clinical proﬁles of SSRI users who have
ungrouped SSRI claim(s). METHODS: A random sample
(N = 1,400,000) of individuals was generated for the
study from de-identiﬁed health care claims data of a large
U.S. health plan. Individuals who had been continuously
enrolled in the health plan for the 24-month full period
between April 1, 1999 and March 30, 2001 were eligible
for the study. Those with at least 1 SSRI pharmacy claim
were selected (N = 74,739). An equal number of individ-
uals without SSRI claims were also selected. Medical and
pharmacy claims data were run through CCG version 3.1
and generated the following groups of individuals: Group
A consisting of non-SSRI users; Group B consisting of
individuals with grouped SSRI claims; and Group C con-
sisting of individuals with at least one ungrouped SSRI
claim. RESULTS: The average age in each group was: A—
36, B—42, and C—45. Prevalence of SSRI indicated dis-
orders in each group were: A—54, B—724, and C—56
(cases/1000 members). On average, individuals in group
C had 7 SSRI prescriptions whereas individuals in group
B had 9. The average health care utilization for each
group was: A—$4051, B—$9574, and C—$7920. The
average number of unique providers visited for each
group was: A—9.5, B—16.5, and C—13.4. Of the
grouped SSRI prescriptions, psychiatrists prescribed
25.0% whereas only 7.6% of the ungrouped SSRI were
prescribed by psychiatrists. CONCLUSION: Signiﬁcant
differences exist between individuals with and without
ungrouped SSRI prescriptions and may illuminate the
cause of ungrouped SSRI prescriptions.
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OBJECTIVE: This study was designed to identify predic-
tors of duration of visits among patients diagnosed 
with depression in the ambulatory medical care settings.
METHOD: Data from the 1999 National Ambulatory
Medical Care Survey (NAMCS) were used to identify
patients 10 to 75 years old with a documented diagnosis
of depression (ICD-9-CM = 296.2–296.36; 300.4 or
311). The unweighted sample size was 826. Multivariate
linear regression was used to identify the predictors.
Model variables included patients’ characteristics, treat-
ment patients received, and physicians’ characteristics.
RESULTS: Among the factors predictive of the duration
of visits, signiﬁcant factors include female patients, Med-
icaid patients, capitated payment, seen by other providers
and receipt of psychotherapy. After controlling for other
factors, physicians spend about 2.19 (95% CI: 0.03,4.35)
minutes longer with female patients during the visit than
male patients; physicians spend 8.13 (95% CI: 1.93,
14.32) minutes less with Medicaid patients compared
with patients with private insurance; Physicians spend
8.57 (95% CI: 3.96, 13.18) minutes less with patients in
a capitated visit compared to a non-capitated visit; Estab-
lished patients receive 12.30 (95% CI: 5.30, 19.31)
minutes less with the physician provider compared with
non- established patients; Patients who receive care from
other providers besides a physician such as a physician
assistant, a nurse practitioner, a nurse midwife, a R.N., a
L.P.N., a medical or nursing assistant spend 6.96 minutes
(95% CI: 3.14, 10.77) less with the physician compared
with patients who don’t receive care from other
providers. Patients who receive psychotherapy spend
15.60 (95% CI: 11.04, 20.06) minutes more than patients
who don’t receive psychotherapy. CONCLUSION: Med-
icaid, capitation payment and seen by other providers
were three signiﬁcant and negative predictors of the dura-
tion of the visit. Economic incentives may cause providers
to spend less time with patients or substitute with rela-
tive cheaper health care professionals.
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OBJECTIVES: To estimate the prevalence and trends of
antipsychotic polypharmacy, categorize polypharmacy
according to the type of antipsychotic and duration of
use, and contrast polypharmacy usage patterns with pub-
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lished treatment guidelines. METHODS: Medicaid recip-
ients at least 16 years of age with at least one primary
diagnosis of schizophrenia (ICD-9-CM = 295) between
1998–2000 were identiﬁed from the Georgia and Cali-
fornia (20% random sample) Medicaid claims databases.
Polypharmacy cohorts were built in a hierarchical fashion
based on the antipsychotic use proﬁle of the schizophre-
nia patients and in accordance with published treatment
guidelines i.e. any polypharmacy, clozapine (clozapine +
atypical; clozapine + conventional), non-clozapine (atyp-
ical + atypical; conventional + conventional; and atypical
+ conventional) and long-term i.e. duration of use >2
months. Total 3-year prevalence of polypharmacy,
mean/median duration of episodes and year wise trends
in usage were estimated. All results were reported by state
and in aggregate. RESULTS: Out of a total of 31,435
persons with schizophrenia, the overall prevalence of
antipsychotic polypharmacy was 40% (n = 12,549, mean
age: 43 years, Caucasian: 47%, female: 48%) over
1998–2000 and was 46% in California compared to 35%
Georgia (p < 0.0001). Long-term polypharmacy (expo-
sure > 2 months) had a prevalence rate of 23% (n = 7222)
with a long-term episode lasting a median of 197 days.
Among the long-term groups, non-clozapine polyphar-
macy was around 8 times more prevalent than clozapine
polypharmacy (p < 0.0001) and long term non-clozapine
atypical + conventional had the highest prevalence of
16%. Except for clozapine + conventional (no change)
and conventional + conventional (decreased) polyphar-
macy, all polypharmacy prevalences increased from 1998
through 2000 (Cochran-Armitage test; p < 0.0001).
CONCLUSIONS: The overall polypharmacy prevalence
rate of 40% is similar to that observed in other studies.
Average long-term polypharmacy with a median duration
of over 6 months and signiﬁcantly higher prevalence of
non-clozapine vs. clozapine polypharmacy contradicts
treatment guidelines and may be a cause for concern.
PMH17
USE OF SEDATIVE/HYPNOTIC AGENTS BY AN
ELDERLY AMBULATORY POPULATION
Carlson AM1, Morris LS2
1Data Intelligence Consultants LLC, Eden Prairie, MN, USA;
2IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: The purpose of this study was to investi-
gate use sedative/hypnotic drugs in a generally ambula-
tory population of persons 65+ years of age. Clinical
literature suggests that use of these agents is accompanied
by physical and mental functioning declines that pose par-
ticular concerns for non-institutionalized older individu-
als. METHODS: Retrospective analysis of sedative/
hypnotic claims from a database. Persons with at least
one prescription for a sedative/hypnotic in a 12-month
study period (January 1, 2001–December 31, 2001), who
were 65 years of age or older and were continuously
enrolled in the 6 months prior to the end of the study
period were included. Sedative/hypnotic agents included
barbiturate and non-barbiturate sedative hypnotics alone
or in combinations. Claims histories were used to identi-
ﬁed naïve users; current use was categorized as acute,
limited, or continuous based on days supply and reﬁll pat-
terns. RESULTS: Eight and a half percent of the 313,038
persons meeting inclusion criteria had at least one claim
for sedative/hypnotic agents. Of these 38% (n = 10,010)
were classiﬁed as naïve users. For these patients the mean
number of days of therapy for the initial prescription was
28.0 ± 15.1. Only 9% of naïve users received an initial
prescription for less than a 10 day supply; 8% received
initial prescriptions for >31 days; some up to a 90-day
supply. Short-term use was identiﬁed in less than 1/3 of
naïve users; 15% continued sedative/hypnotic use for
greater than 3 months. Twenty-eight percent of naïve
users received prescriptions for agents identiﬁed as poten-
tially inappropriate in elderly patients (21% received a
“never-use” drug). CONCLUSIONS: Sedative/hypnotic
utilization patterns in elderly ambulatory patients, par-
ticularly the evidence of non-adherence to clinical pre-
scribing recommendations related to initial drug selection
and days of therapy, should be of concern.
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OBJECTIVES: To examine treatment and pharmaceuti-
cal utilization patterns for patients receiving risperidone,
olanzapine or quetiapine in a VA system. METHODS:
This study used electronic claims data (VISTA system) 
to identify subjects prescribed atypical antipsychotics
between January 1, 1996 and June 30, 2001. Included
subjects were prescribed at least one study medication
and had at least two markers for any of the following
mental health disorders: bipolar, depression, schizophre-
nia, schizoaffective disorder, dementia, or PTSD. Demo-
graphics, average dose by diagnosis, adherence to VA
Guidelines, duration of therapy, concomitant medica-
tion use, and switching were analyzed descriptively.
RESULTS: Of 7658 total study patients, the following
number of patients received at least 1 prescription for the
following drugs: olanzapine (4363), risperidone (3878),
quetiapine (1387). The proportion of subjects with a
schizophrenia diagnosis receiving dose ranges consistent
with VA published guidelines for olanzapine, risperidone,
and quetiapine were 90, 75 and 41% respectively, but
varied greatly by diagnosis. Mean duration of therapy for
